Ombitasvir/paritaprevir/ritonavir and dasabuvir
CADTH
Record ID 32016000179
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/RTV and DSV) be listed for the treatment of adults with genotype 1 chronic hepatitis C virus (CHC) infection, including those with compensated cirrhosis, if the following clinical criterion and conditions are met. Clinical criterion: Liver fibrosis stage of ≥ 2. Conditions: Treatment should be initiated by physicians with experience in the management of CHC patients. Drug plan costs for OBV/PTV/RTV and DSV should not exceed the drug plan costs of other interferon-free regimens for the treatment of CHC.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/sites/default/files/cdr/complete/SR0406-Holkira-Pak-July-22-15-e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Hepatitis C, Chronic
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.